Brian I. Rini, MD

Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses how data should be looked at between 2 combinations for the treatment of renal cell carcinoma (RCC). He says atezolizumab (Tecentriq) plus bevacizumab (Avastin) will never be compared head to head with ipilimumab (Yervoy) plus nivolumab (Opdivo).

Having these 2 combinations is great from a clinician standpoint as they are additional options for patients with RCC. One combination could be more tolerable and suitable for some patients than the other combination, Rini says. It is the clinician&rsquo;s job to then figure out which combination is best.

Videos

Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses how data should be looked at between 2 combinations for the treatment of renal cell carcinoma. He says atezolizumab plus bevacizumab will never be compared head to head with ipilimumab plus nivolumab.

Selecting Atezolizumab Plus Bevacizumab Versus Ipilimumab Plus Nivolumab in RCC

Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses the rationale for combining atezolizumab (Tecentriq) and bevacizumab (Avastin) for patients with metastatic renal cell carcinoma (mRCC) in the IMmotion151trial.

Both of these agents have proven to be active as monotherapies, and as such, it seemed rational to combine them. Additionally, VEGF has immune-suppressive effects, including promoting myeloid-derived suppressor cells, regulatory T cells, etc. By suppressing VEGF, the microenvironment is more favorable for the immunotherapy to act.

Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses the rationale for combining atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma in the&nbsp;IMmotion151trial.

Brian I. Rini, MD | Authors

Articles

Selecting Atezolizumab Plus Bevacizumab Versus Ipilimumab Plus Nivolumab in RCC

Rationale for Combining Atezolizumab/Bevacizumab in mRCC